作者:于一江 单位:淮安市中医院内分泌科 来源:医学界内分泌频道 01 02 03 04 05 06 参考文献: [1]何秉贤.二甲双胍在高血压防治中应用的现代观点[J].中华高血压杂志,2018,26(06):508-509. [2]Racine Jenna L,Adams Jacquelyn H,Antony Kathleen M,el.Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.[J].American journal of perinatology,2021,38(11). [3]Ouyang Hong,AlMureish Abdulrahman,Wu Na.Research progress of metformin in gestational diabetes mellitus:a narrative review.[J].Annals of palliative medicine,2021,10(3). [4]杨周生,陈晓宇.二甲双胍多效能药理作用的研究进展[J].中国临床新医学,2021,14(04):422-426. [5]许桂炎,应晓蕾,曹海辉.二甲双胍治疗高血压并发代谢综合征的临床效果[J].全科医学临床与教育,2017,15(01):89-91. [6]苏馨,胡蓉.高血压合并糖尿病血压控制的探讨[J].重庆医学,2018,47(16):2219-2222. [7]刘思绪,于胜钦,张曙影.阿卡波糖心血管获益机制及安全性的研究进展[J].实用心脑肺血管病杂志,2019,27(11):102-106. [8]周鹤铭,周雁苹.吡格列酮辅助治疗老年2型糖尿病并高血压的可行性[J].慢性病学杂志,2019,20(09):1384-1385+1388. [9]臧永军,龙朦朦,刘东,等.吡格列酮治疗2型糖尿病的研究进展[J].中国医药指南,2017,15(36):4-5. [10]张秀龙,占长河.吡格列酮联合阿卡波糖治疗老年2型糖尿病并高血压的临床疗效[J].临床合理用药杂志,2019,12(09):11-12+14. [11]Kvandova M,Barancik M,Balis P,Puzserova A,Majzunova M,Dovinova I.The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability,renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.[J].Journal of physiology and pharmacology:an official journal of the Polish Physiological Society,2018,69(2). [12]郭彩红,高秀莹.达格列净对2型糖尿病伴代谢综合征患者代谢指标影响[J].临床军医杂志,2018,46(05):585-587. [13]郝雁红,吴清,李云,等.达格列净在2型糖尿病合并高血压患者中的临床应用[J].中国当代医药,2021,28(18):12-16. [14]王菲,卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,41(03):231-234. [15]陈添玉,陈琪莹,张月珍.卡格列净对2型糖尿病患者心血管因素影响的Meta分析[J].药物流行病学杂志,2021,30(04):239-244+288. [16]Kario Kazuomi,Okada Kenta,Kato Mitsutoshi,Nishizawa Masafumi,Yoshida Tetsuro,Asano Tsuguyoshi,Uchiyama Kazuaki,Niijima Yawara,Katsuya Tomohiro,Urata Hidenori,Osuga Jun-Ichi,Fujiwara Takeshi,Yamazaki Shoji,Tomitani Naoko,Kanegae Hiroshi.24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension:Results from the Randomized,Placebo-Controlled SACRA Study.[J].Circulation,2018,139(18). [17]周佩,唐湘宇,邓云霞,等.SGLT-2抑制剂——恩格列净的心血管保护作用及机制研究进展[J].中国医药导刊,2021,23(11):823-827. [18]孙永,田琳,吴让兵,等.2型糖尿病治疗新药恩格列净的研究现状[J].中国糖尿病杂志,2018,26(06):523-528. [19]Dilip Sharma,Suril Verma,Shivani Vaidya,el.Recent updates on GLP-1 agonists:Current advancements&challenges[J].Biomedicine&Pharmacotherapy,2018,108. [20]赵延珍,杜婧.GLP-1受体激动剂治疗2型糖尿病的研究进展[J].老年医学研究,2021,2(03):55-60. [21]陈涯,王艳萍,张亮,等.利拉鲁肽对2型糖尿病合并动脉粥样硬化患者血糖、血脂、血压和颈动脉斑块的影响[J].海南医学院学报,2019,25(10):730-734. [22]徐庆海,马颖,吴艳春,等.利拉鲁肽对2型糖尿病合并高血压患者血糖、血压及血脂的影响[J].山东医药,2017,57(21):77-79. [23]Younes Subhi Talal,Maeda Kenji J,Sasser Jennifer,el.The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.[J].American journal of physiology.Heart and circulatory physiology,2020,318(1). [24]张学辉,李娟.利拉鲁肽降压效应机制的研究进展[J].临床医学研究与实践,2021,6(08):196-198. [25]Zhang Jianqiang,Chen Qiuyue,Zhong Jixin,Liu Chaohong,Zheng Bing,Gong Quan.DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy:Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.[J].Frontiers in immunology,2019,10. [26]杜蓥漩,王慧.西格列汀对糖尿病合并高血压患者血压、动脉僵硬度和内皮功能的影响[J].广西医学,2020,42(10):1193-1197. [27]陈昇.西格列汀辅助治疗糖尿病并高血压对患者糖脂代谢、血管内皮功能的影响[J].糖尿病新世界,2020,23(24):91-93+102. |
|